Monovo (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors inside skin cells, modifying gene transcription to suppress the production of inflammatory cytokines, prostaglandins, and leukotrienes. This anti‑inflammatory action decreases vascular permeability and immune cell infiltration, providing relief from skin inflammation.

The prescribed dose of Monovo is determined by the treating physician based on the severity of the skin condition, patient age, and treatment area. The prescriber will specify the amount to apply, frequency, and duration of therapy on the product label or prescription.

Safety of mometasone furoate in pregnancy or lactation has not been fully established. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Monovo.

To order Monovo, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Monovo (mometasone furoate) is a high‑potency corticosteroid, offering stronger anti‑inflammatory effects than low‑potency agents like hydrocortisone, but with a lower risk of systemic side effects compared with very high‑potency steroids such as clobetasol. Choice of therapy depends on disease severity, treatment area and physician judgment.

Monovo should be stored at ambient temperature, preferably below 25 °C, in its original packaging. Keep the product away from excess moisture, direct sunlight, and heat sources to maintain its stability and potency throughout its shelf life.

Monovo is applied topically to the affected skin area. The prescribed amount is spread thinly and gently massaged into clean, dry skin, typically once or twice daily, unless otherwise directed by a healthcare professional. Hands should be washed before and after application.

Serious risks include skin atrophy or thinning with prolonged use, secondary infections (bacterial, fungal, viral), and systemic effects such as adrenal suppression or Cushingoid features if large areas are treated or used for extended periods. Patients should report any unusual symptoms promptly.

Monovo should be avoided in individuals with known hypersensitivity to mometasone furoate or any formulation components, untreated skin infections, or in patients where systemic corticosteroid exposure is contraindicated. Children under two years of age should not use high‑potency topical steroids without specialist guidance.